Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333482 | 0.88 | KMT2A (0.48) | SLC6A4SLC6A3L3MBTL1KMT2ALMNA | |
| SCHEMBL25335134 | 0.87 | NR1H2 (0.54) | SLC6A4SLC6A3L3MBTL1KMT2ALMNA | |
| SCHEMBL7744542 | 0.86 | ALDH1A1 (0.53) | L3MBTL1KMT2AKCNH2OPRK1USP2 | |
| Hydrochloric Acid SCHEMBL30028803 | 0.85 | ALDH1A1 (0.52) | L3MBTL1KMT2AKCNH2OPRK1USP2 | |
| SCHEMBL11094118 | 0.83 | LMNA (0.56) | L3MBTL1KMT2ALMNAKCNH2OPRK1 | |
| SCHEMBL7371335 | 0.83 | LMNA (0.56) | L3MBTL1KMT2ALMNAKCNH2OPRK1 | |
| SCHEMBL15405283 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A3L3MBTL1KMT2AKCNH2 | |
| SCHEMBL6121340 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A3L3MBTL1KMT2AKCNH2 | |
| SCHEMBL29641206 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A3L3MBTL1KMT2AKCNH2 | |
| SCHEMBL16765154 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A3L3MBTL1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | SLC6A4 3031/4885SLC6A3 2132/4885L3MBTL1 1158/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | SLC6A4 2612/4885SLC6A3 2074/4885L3MBTL1 1179/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | SLC6A4 3109/4885SLC6A3 2220/4885L3MBTL1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.